

## CARDIO3 BIOSCIENCES WILL BE PRESENT AT ODDO MIDCAP FORUM

**Mont-Saint-Guibert, Belgium** - Cardio3 BioSciences (C3BS) (*Euronext Brussels and Paris: CARD*), a leader in the development of regenerative therapies, announces its participation in the **18<sup>th</sup> edition of the ODDO forum**, dedicated to European Midcaps, that will take place on 8 and 9 January 2015 in Lyon. The ODDO Midcap forum is renowned as the largest event dedicated to European listed companies.

This event will enable Cardio3 BioSciences to highlight its on-going development programs and strategic vision for the future to potential investors.

**Patrick Jeanmart, CFO of Cardio3 BioSciences, commented:** *"The ODDO Midcap forum is an excellent opportunity to increase Cardio3 Biosciences' visibility towards European investors, but most importantly it is a unique occasion to present Cardio3 Biosciences' development potential, positioning and strategic vision."*

\*\*\* END \*\*\*

For more information, please contact:

**Cardio3 BioSciences**

Christian Homsy, CEO

Julie Grade, Corporate Communications Manager

[www.c3bs.com](http://www.c3bs.com)

Tel. : +32 10 39 41 00

[jgrade@c3bs.com](mailto:jgrade@c3bs.com)

**For Europe: Citigate Dewe Rogerson**

Chris Gardner

Tel : +44 (0) 207 638 9571

[Chris.Gardner@citigatedr.co.uk](mailto:Chris.Gardner@citigatedr.co.uk)

**For the U.S: Rx Communications Group**

Eric Goldman

Tel: +1 917 322 2563

[egoldman@RxIR.com](mailto:egoldman@RxIR.com)

To subscribe to Cardio3 BioSciences' newsletter, visit [www.c3bs.com](http://www.c3bs.com).

 Follow us on Twitter [@Cardio3Bio](https://twitter.com/Cardio3Bio).

#OddoMidcapForum

**About Cardio3 BioSciences**

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of unmet medical needs. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure<sup>®</sup> is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure<sup>®</sup> consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis.



PRESS RELEASE

17 DECEMBER 2014

9AM CET

Cardio3 BioSciences has also developed C-Cath<sub>ez</sub><sup>®</sup>, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

*C3BS-CQR-1, C-Cure, C-Cath<sub>ez</sub>, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath<sub>ez</sub> logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.*